SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Zentek Ltd - ZEN

16 Jan 2023 07:00 AM
04 Jan 2023 08:17 AM
01 Oct 2022 07:11 PM
10 Sep 2022 07:02 AM
09 Sep 2022 12:53 PM
17 Jun 2022 03:30 PM
20 Mar 2022 02:58 PM
09 Nov 2021 04:11 PM
09 Nov 2021 03:59 PM
09 Nov 2021 01:22 PM
27 Oct 2021 10:36 AM
30 Aug 2021 06:25 PM
30 Aug 2021 05:57 PM <--
07 Mar 2020 12:58 PM
07 Mar 2020 05:58 AM
07 Mar 2020 04:55 AM
09 Sep 2015 02:13 PM
15 May 2015 03:16 PM
12 May 2015 12:39 PM
12 May 2015 11:39 AM
12 May 2015 10:45 AM
12 May 2015 09:59 AM
02 Sep 2014 03:09 AM
12 Jan 2014 01:55 PM
07 Aug 2013 11:57 AM
07 Jul 2013 06:49 PM
03 Jul 2013 11:22 AM
25 May 2013 08:41 PM

Return to Zentek Ltd - ZEN
 
A discussion forum for ZEN Graphene Solutions and graphene/graphite related subjects

ZEN Graphene Solutions - Graphene-Enhanced Materials for Next-Level Performance

Clean Technology.
Green Energy.
Advanced Materials.
Healthcare Solutions.

Prevention

ZEN’s patent-pending graphene-based biocidal coating has 99%+ proven effectiveness against viruses, fungi and bacteria.
We are working with TreborRx and other partners globally to bring this much needed innovation forward to better protect our healthcare workers and the public. Given the effectiveness and versatility of our coating, we have an agreement in place to coat nitrile gloves and are exploring other applications that can bring an added layer of protection to the healthcare and other industries globally.

Detection

ZEN is evaluating development of a rapid, ultrasensitive and low-cost bio-sensor to detect the presence of the SARS-CoV-2 antigens and potentially others.
ZEN Graphene Solutions Announces Exclusive Worldwide Rights to Commercialize Rapid, Saliva-Based COVID-19 Antigen Testing Technology zengraphene.com

Treatment

Broad-Spectrum Effectiveness
With 99.9% effectiveness against bacteria, fungi and viruses, the ability to achieve those levels with an extremely low minimum inhibitory concentration (MIC) and excellent safety results, ZEN’s patent-pending graphene-based formulation is a potential game changer for treating human-contracted pathogens and infectious disease management.

“In the clinical setting, if the compound can be shown to be safe and effective, it could provide a breakthrough alternative therapy with potentially significant impact on the practice of family medicine.”

Dr. Tony Mazzulli, MD, FRCPC, FACP, Microbiologist-in-Chief and Infectious Disease Specialist at University Health Network/Mount Sinai Hospital


Source: zengraphene.com

Corporate Presentations: zengraphene.com